Mahesh Karande Receives Stock Award at Omega Therapeutics Inc (OMGA) — SEC Form 4, Feb 09, 2024
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Mahesh Karande CIK 0001860422 |
Director
CEO
|
Mahesh Karande at Omega Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Omega Therapeutics Inc
| 2023-03-02 | Award | — | View |
| 2022-10-28 | Award | — | View |
| 2022-03-11 | Award | — | View |
| 2022-02-03 | Exercise | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.59 | 2024-02-07 | A - Award/Grant | 209,551 A | $0.00 | 2034-02-06 | 209,551 Common Stock | Direct |
| Stock Option (Right to Buy)F2 | $3.59 | 2024-02-07 | A - Award/Grant | 314,326 A | $0.00 | 2034-02-06 | 314,326 Common Stock | Direct |
Footnotes (2)
- F1
- The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Show more
- F2
- The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter, such that the option will become fully vested and exercisable on February 7, 2028, subject to acceleration on the one-year anniversary of the consummation of a business development deal by the Issuer with terms that satisfy its corporate goals for business development collaborations and subject to the Reporting Person's continued service to the Issuer through each such vesting date. Show more
Related filings at Omega Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
1
institutional managers reporting a position
Largest by reported value
5%+ Holders · 13D/G
2 filers
Other insiders at Omega Therapeutics Inc
GET /v1/forms/4/0000950170-24-013364
API docs
View Original SEC Filing